Skip to main content

Table 1 Patient characteristics of men diagnosed with non-metastatic prostate cancer receiving radical treatment according to the Cambridge Prognostic Group (CPG) classification

From: Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation

CPG

Criteria

10-year risk of dying from prostate cancer without treatment* (%)

10-year risk of dying from prostate cancer with treatment* (%)

1

Gleason score 6 (grade group 1)

AND PSA < 10 ng/ml

AND stages T1–T2

4.2

1.2

2

Gleason score 3 + 4 = 7 (grade group 2)

OR PSA 10–20 ng/ml AND stages T1–T2

4.7

2.3

3

Gleason score 3 + 4 = 7 (grade group 2)

AND PSA 10–20 ng/ml

AND stages T1–T2

OR

Gleason score 4 + 3 = 7 (grade group 3)

AND stages T1–T2

15.1

3.2

4

One of the following:

Gleason score 8 (grade group 4)

OR PSA > 20 ng/ml

OR stage T3

N/A**

5.8

5

Any combination of Gleason score 8 (grade group 4), PSA > 20 ng/ml or stage T3

OR Gleason score 9–10 (grade group 5)

OR stage T4

N/A**

13.7

  1. *Mortality is taken from Gnanapragasam et al. [3]
  2. *No reliable data is available for untreated men with CPG4 or CPG5